A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2011
12/06/2011	CA2512933C A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
12/06/2011	CA2495341C Water-swellable polymers
12/06/2011	CA2491317C Modafinil pharmaceutical compositions
12/06/2011	CA2470837C Matrix-forming composition containing pectin
12/06/2011	CA2470791C Soft drink replacer
12/06/2011	CA2465248C Proteins stabilized with polysaccharide gums
12/06/2011	CA2460489C Pegylated and diglycosylated erythropoietin
12/06/2011	CA2405031C Guaifenesin sustained release formulation and tablets
12/06/2011	CA2361766C Gcsf conjugates
12/06/2011	CA2328783C Human procalcitonin and the preparation and use thereof
12/06/2011	CA2309954C Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
12/06/2011	CA2305683C Immunogenic peptides from the hpv e7 protein
12/06/2011	CA2304313C Composition and method for enhancing paracellular transport across cell layers
12/04/2011	CA2799391A1 Improved process for a folate-targeted agent
12/01/2011	WO2011150418A2 Compositions and methods for treating pathologies
12/01/2011	WO2011150258A1 Dose selection of adjuvanted synthetic nanocarriers
12/01/2011	WO2011150240A1 Nanocarrier compositions with uncoupled adjuvant
12/01/2011	WO2011150229A2 Dietary supplements containing extracts of cinnamon and methods of using same to promote enhanced sirtuin, cell and telomere integrity
12/01/2011	WO2011150212A2 Magnetic nanoparticles
12/01/2011	WO2011150144A2 Aqueous formulations for coating microneedle arrays
12/01/2011	WO2011150127A2 Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells
12/01/2011	WO2011150088A1 Optimized drug conjugates
12/01/2011	WO2011150082A2 Methods of utilizing the arrestin-2/stam-1 complex as a therapeutic target
12/01/2011	WO2011150073A2 Compositions comprising the nc2 domain of collagen ix and methods of using same
12/01/2011	WO2011150022A2 Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
12/01/2011	WO2011149814A2 Effervescent composition for forming a gelled composition, tablet for forming a gelled composition, and method of making a gelled composition
12/01/2011	WO2011149757A1 Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
12/01/2011	WO2011149472A1 Method for preparing an enriched igg composition from plasma
12/01/2011	WO2011149349A1 2-iminobiotin formulations and uses thereof
12/01/2011	WO2011149061A1 Composite body containing inactivated virus particle and use thereof
12/01/2011	WO2011149016A1 Complex containing thrombolytic enzyme
12/01/2011	WO2011149006A1 Aqueous composition to be contained in container
12/01/2011	WO2011148941A1 Sugar responsive gel and medicine administering device
12/01/2011	WO2011148829A1 Pet food
12/01/2011	WO2011148640A1 Blood flow promoter and external preparation
12/01/2011	WO2011148209A2 New use of diatomaceous earth in the pharmaceutical industry
12/01/2011	WO2011148116A2 Modified hyaluronic acid, method for manufacturing same and uses thereof
12/01/2011	WO2011147921A1 Stable multi-dose compositions comprising an antibody and a preservative
12/01/2011	WO2011147762A2 Stabilized radiopharmaceutical composition
12/01/2011	WO2011147704A1 Ultrasound coupling liquid and container
12/01/2011	WO2011147536A2 Topical pharmaceutical compositions
12/01/2011	WO2011147471A1 Antidementia oral pharmaceutical solutions
12/01/2011	WO2011147280A1 Injection of enrofloxacin and producing method thereof
12/01/2011	WO2011147185A1 Immunosuppressant j2 - sodium alginate microsphere, preparation method and use thereof
12/01/2011	WO2011147175A1 PREPARATION OF MICROVESICLE-siRNA COMPLEXES AND USE THEREOF IN AIDS TREATMENT
12/01/2011	WO2011147034A1 Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof
12/01/2011	WO2011147025A1 Controlled release dosage form comprising quetiapine
12/01/2011	WO2011126352A3 Anti-tuberculosis preparation based on an inclusion complex of cyclodextrin with rifampicin and a method for the preparation thereof
12/01/2011	WO2011124739A4 Silica nanoparticles for the intracellular diffusion of poorly soluble bioactive agents
12/01/2011	WO2011119059A4 Photo-crosslinked gellan gum-based hydrogels: preparation methods and uses thereof
12/01/2011	WO2011115489A3 Spray-pumpable composition suitable for topical skin application
12/01/2011	WO2011114239A3 Fat-binding compositions
12/01/2011	WO2011086143A3 Liver targeting domain antibodies
12/01/2011	WO2011081443A3 Target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and manufacturing method thereof
12/01/2011	WO2011081406A3 Macromolecule for delivering protein, polypeptide or peptide drugs and a production method for the same, and a slow release composition for protein, polypeptide or peptide drugs and a production method for the same
12/01/2011	WO2011079279A3 Nanoconjugates and nanoconjugate formulations
12/01/2011	WO2011063921A8 Acceleration of wound healing by a tissue inhibitor of metalloproteinases (timp) linked to glycosylphosphatidylinositol (gpi)-anchors
12/01/2011	WO2011063336A3 Secondary site of antigen stimulation for therapeutic vaccination
12/01/2011	WO2011049713A3 Stabilized glucagon solutions
12/01/2011	WO2011034604A3 Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
12/01/2011	WO2011016043A3 Antibiotic drug delivery and potentiation
12/01/2011	WO2010105842A9 Preparation for external application
12/01/2011	US20110294981 Chimeric t1r taste receptor polypeptides and nucleic acid sequences encoding and cell lines that express said chimeric t1r polypeptides
12/01/2011	US20110294904 Dry Granulation Binders, Products, and Use Thereof
12/01/2011	US20110294903 Large particle size crystallised maltitol powder, method for preparing same and applications thereof, particularly in chocolate production
12/01/2011	US20110294902 Pharmaceutical compositions providing enhanced drug concentrations
12/01/2011	US20110294889 Infusion and Injection Solution of Levodopa
12/01/2011	US20110294871 Lipids, lipid complexes and use thereof
12/01/2011	US20110294845 Parenteral formulations
12/01/2011	US20110294765 Procedure for obtaining an aqueous dispersion of alcohols and acids from jojoba oil, processes for obtaining self-emulsified jojoba oil, aqueous dispersions and emulsions of jojoba oil in the same and pharmaceutical or cosmetic compositions comprising the same
12/01/2011	US20110294734 Pharmaceutical compositions comprising tgf-beta 1 inhibitor peptides
12/01/2011	US20110294717 Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers
12/01/2011	US20110293732 Nanoparticles made of amorphous cellulose
12/01/2011	US20110293711 Utilization of Dialkylfumarates
12/01/2011	US20110293703 Aminoalcohol lipidoids and uses thereof
12/01/2011	US20110293700 Nanocarrier compositions with uncoupled adjuvant
12/01/2011	US20110293699 Hydrogel implants with varying degrees of crosslinking
12/01/2011	US20110293695 Amphoteric liposomes
12/01/2011	US20110293687 Hydrogel implants with varying degrees of crosslinking
12/01/2011	US20110293675 Coatings of acrylamide-based copolymers
12/01/2011	US20110293669 Hydrogel implants with varying degrees of crosslinking
12/01/2011	US20110293663 Pharmaceutical botulinum toxin compositions
12/01/2011	US20110293647 Immunogenic lhrh compositions and methods relating thereto
12/01/2011	US20110293592 Method of treating coronary arteries with perivascular delivery of therapeutic agents
12/01/2011	US20110293539 Film containing compositions
12/01/2011	US20110293538 Use of rubusoside for reducing or suppressing certain unpleasant taste impressions
12/01/2011	US20110293515 Heterofunctional segment-poly (ethylene glycol) polymers as delivery vehicles
12/01/2011	CA2837129A1 2-iminobiotin formulations and uses thereof
12/01/2011	CA2828605A1 Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
12/01/2011	CA2800910A1 Pharmaceutical dosage form containing an antipsychotic agent
12/01/2011	CA2800744A1 Insulin-like growth factor 1 receptor binding peptides
12/01/2011	CA2800731A1 Compositions and methods of using living and non-living bioactive devices with components derived from self-renewing colony forming cells cultured and expanded in vitro
12/01/2011	CA2800693A1 Delivery of therapeutic agents to inflamed tissues using folate-targeted agents
12/01/2011	CA2800595A1 Compositions comprising the nc2 domain of collagen ix and methods of using same
12/01/2011	CA2800375A1 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
12/01/2011	CA2800272A1 Removal of serine proteases by treatment with finely divided silicon dioxide
12/01/2011	CA2800253A1 Aqueous formulations for coating microneedle arrays
12/01/2011	CA2800188A1 Stable multi-dose compositions comprising an antibody and a preservative
12/01/2011	CA2800155A1 Method for preparing an enriched igg composition from plasma
12/01/2011	CA2799771A1 Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients

1 ... 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 ... 1712